GeneQuine wins Merck’s 2016 European Emerging Biotech Grant Program

The Emerging Biotech Grant Program, sponsored by Merck KGaA, helps upcoming biotech companies with financial and research support.

GeneQuine won the first prize, which is €100,000 in products and services from the Merck group. The grant will accelerate GeneQuine's development of a novel gene therapy platform and support the lead program in osteoarthritis. Labiotech, the leading digital media covering the European Biotech industry, published an article on Merck’s Emerging Biotech Initiative featuring GeneQuine as the winner.

Link to article